It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Introduction: Idiopathic hypertrophic cranial pachymeningitis (IHCP) is a rare pathological entity which is diagnosed after the exclusion of secondary reasons. Most frequently, IHCP is related to rheumatological diseases such as rheumatic arthritis, sarcoidosis, anti-neutrophil cytoplasmic antibody-associated vasculitis, and IgG4-related disorders. The inflammatory process concerns dura mater and manifests with symptoms of cranial nerve damage or compression.
Case description: A 59-year-old Caucasian man presented with transitional episodes of tinnitus and an unspecific headache. Imaging studies (magnetic resonance imaging – MRI) demonstrated a thickened dura mater. Lymphoma was suspected due to an abnormal flow cytometric analysis of a cerebrospinal fluid (CSF) sample. Hematological diagnostics including bone marrow biopsy, whole body computed tomography (CT) and digestion tract examination were performed leading to the exclusion of hematological malignancy. The patient underwent surgery, and a specimen from the lesion was obtained. On this basis, intracranial idiopathic hypertrophic pachymeningitis was diagnosed. First line treatment strategy was introduced with corticosteroids with a gradual dose reduction. After the 48-month follow-up, we observed an alleviation of symptoms with a gradual significant decrease in the thickening of dura matter with almost complete resolution.
Conclusions: Idiopathic hypertrophic pachymeningitis should be considered in the differential diagnosis of a thickened dura mater. Administration of steroids appears reasonable as a first line treatment of IHCP.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details







1 Pomeranian Medical University in Szczecin, Department of General Pathology, Powstańców Wlkp. 72, 70-111 Szczecin, Poland; University Hospital No. 1 of Pomeranian Medical University in Szczecin, Department of Hematology with Bone Marrow Transplantation Unit, Unii Lubelskiej 1, 71-252 Szczecin, Poland
2 University Hospital No. 1 of Pomeranian Medical University in Szczecin, Clinic of Neurosurgery and Pediatric Neurosurgery, Unii Lubelskiej 1, 71-252 Szczecin, Poland
3 University Hospital No. 1 of Pomeranian Medical University in Szczecin, Department of Hematology with Bone Marrow Transplantation Unit, Unii Lubelskiej 1, 71-252 Szczecin, Poland
4 University Hospital No. 1 of Pomeranian Medical University in Szczecin, Department of Neurology, Unii Lubelskiej 1, 71-252 Szczecin, Poland
5 University Hospital No. 1 of Pomeranian Medical University in Szczecin, Department of Interventional Radiology, Unii Lubelskiej 1, 71-252 Szczecin, Poland
6 Pomeranian Medical University in Szczecin, Department of General Pathology, Powstańców Wlkp. 72, 70-111 Szczecin, Poland